Nature Reviews Drug Discovery contents February 2017 Volume 16 Number 2 pp 71-147

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2017 Volume 16 Number 2		Advertisement
2015 2-year Impact Factor 47.120 Journal Metrics 2-year Median 31	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Cornerstones of CRISPR–Cas in drug discovery and therapy Christof Fellmann, Benjamin G. Gowen, Pei-Chun Lin, Jennifer A. Doudna & Jacob E. Corn	Genomics has met its match!  MEET METABOLON, GENOMICS' PERFECT COMPLEMENT Explore the relationship between genotype and phenotype with Metabolon's revolutionary solutions. We turn data into actionable insight unlocking the full potential of the genome. See why genomics and metabolomics are better together. Download our eBook
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Unexplored opportunities in the druggable human genome This poster presents a categorization of human proteins based on the amount of data on them, highlighting a knowledge deficit and indicating novel drug discovery opportunities.  Download the Poster free online Produced with support from: Illuminating the Druggable Genome Knowledge Management Center  (IDG KMC)
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
A new open access journal dedicated to publishing the most important scientific advances in all aspects of genomics and its application in the practice of medicine. Part of the Nature Partner Journals series, the journal is published in partnership with the Center of Excellence in Genomic Medicine Research. Open for submissions >>
Comment: Strategies for delivering value from digital technology transformation Eric D. Perakslis p71 | doi:10.1038/nrd.2016.265 Many organizations are attempting to harness emerging digital technologies and the surge in the amount of health-related data to drive advances in the development and use of medicines. Focusing on just a few well-proven and readily available strategies could enable such organizations to quickly realize greater value from data and digital technologies. Full Text | PDF
NEWS AND ANALYSIS		Top
2016 FDA drug approvals Asher Mullard p73 | doi:10.1038/nrd.2017.14 FDA approval count fell last year, despite a steady regulatory filing rate. PDF
NEWS IN BRIEF 2016 EMA drug approval recommendations Asher Mullard p77 | doi:10.1038/nrd.2017.17 PDF
FDA approves splice-modulating drug Asher Mullard p77 | doi:10.1038/nrd.2017.18 PDF
Cancer reproducibility project yields first results Asher Mullard p77 | doi:10.1038/nrd.2017.19 PDF
Ebola vaccine success Asher Mullard p77 | doi:10.1038/nrd.2017.20 PDF
BIOBUSINESS BRIEFS Market watch: Value of 2016 FDA drug approvals: reversion to the mean? Ulrik Schulze, Michael Ringel, Valery Panier & Mathias Baedeker p78 | doi:10.1038/nrd.2017.8 PDF
BIOBUSINESS BRIEFS Regulatory watch: Outcomes of early health technology assessment dialogues in medicinal product development Francois Maignen, Leeza Osipenko, Pilar Pinilla-Dominguez & Emily Crowe p79 | doi:10.1038/nrd.2016.286 PDF
AN AUDIENCE WITH John Jenkins p80 | doi:10.1038/nrd.2017.2 John Jenkins, former Director of the FDA's Office of New Drugs, discusses approvals standards, breakthrough therapy designation and regulatory science hurdles. PDF
FROM THE ANALYST'S COUCH The immuno-oncology race: myths and emerging realities Stephen Cavnar, Pedro Valencia, Jesse Brock, Judith Wallenstein & Valery Panier p83 | doi:10.1038/nrd.2016.279 This article analyses the huge volume of clinical trial activity for immune checkpoint inhibitors, and discusses the development of the market and strategic trends for immuno-oncology therapies in general. PDF
RESEARCH HIGHLIGHTS Top Genetic disorders: Steps towards epigenetic therapy for PWS p85 | doi:10.1038/nrd.2017.3 PDF Autoimmune diseases: Inhibitor of adaptor protein shows self-antigen selectivity p86 | doi:10.1038/nrd.2017.5 PDF Receptor pharmacology: Picking the pocketome for orphan receptor ligands p86 | doi:10.1038/nrd.2017.6 PDF Cancer: Tumour vessel normalization takes centre stage p87 | doi:10.1038/nrd.2017.4 PDF Anticancer drugs: The fat controller p88 | doi:10.1038/nrd.2017.7 PDF IN BRIEF Alzheimer disease: Identification of novel Aβ inhibitors | Neurodegenerative disease: Pituitary adenylate cyclase activator ameliorates SBMA | HIV: CRISPR screen identifies novel therapeutic targets | Epilepsy: HSP90 inhibition suppresses seizures PDF Drug Discovery JOBS of the week Research Resource Director Weill Cornell Medicine Postdoctoral Position at USC University of Southern California Duke and NCCU Postdoctoral Fellowship in Translational Cancer Disparties Research Duke Cancer Institute Doctoral Students in Molecular Medicine Institute for Molecular Medicine Finland (FIMM) Post Doc - Department of Pathology Thomas Jefferson University (TJU) More Science jobs from Drug Discovery EVENT 9th Ocular Diseases Drug Discovery Conference 20.03.17 San Diego, USA More science events from
Advertisement
Nature Outlook: Precision Medicine Health care that is tailored on the basis of an individual's genes, lifestyle or environment, is not a modern concept. But advances in genetics and the growing availability of health data for researchers and physicians promise to make this new era of medicine more personalized than ever before. Access the Outlook free online Sponsored by: Illumina, Inc.
REVIEWS		Top
Cornerstones of CRISPR–Cas in drug discovery and therapy Christof Fellmann, Benjamin G. Gowen, Pei-Chun Lin, Jennifer A. Doudna & Jacob E. Corn p89 | doi:10.1038/nrd.2016.238 The use of CRISPR–Cas technology for gene editing has rapidly become widespread. Here, Corn and colleagues discuss the applications of this revolutionary tool in drug discovery and development, describing how it could make substantial contributions to target identification and validation, animal models and cell-based therapies. Abstract | Full Text | PDF | Supplementary information
Induced protein degradation: an emerging drug discovery paradigm Ashton C. Lai & Craig M. Crews p101 | doi:10.1038/nrd.2016.211 Small-molecule drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function. This article discusses emerging technologies, such as proteolysis-targeting chimaeras (PROTACs), that exploit cellular quality control machinery to selectively degrade target proteins, which could have advantages over traditional approaches, including the potential to target proteins that are not currently therapeutically tractable. Abstract | Full Text | PDF
Induced pluripotent stem cell technology: a decade of progress Yanhong Shi, Haruhisa Inoue, Joseph C. Wu & Shinya Yamanaka p115 | doi:10.1038/nrd.2016.245 Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago, human iPSCs have been widely used for disease modelling, drug discovery and cell therapy development. This article discusses progress in applications of iPSC technology that are particularly relevant to drug discovery and regenerative medicine, including the powerful combination of human iPSC technology with recent developments in gene editing. Abstract | Full Text | PDF
DNA-encoded chemistry: enabling the deeper sampling of chemical space Robert A. Goodnow, Jr, Christoph E. Dumelin & Anthony D. Keefe p131 | doi:10.1038/nrd.2016.213 DNA-encoded chemistry enables rapid and inexpensive syntheses and screening of vast chemical libraries, and is generating substantial interest and investment in the pharmaceutical industry. Here, Goodnow and colleagues provide an overview of the steps involved in the generation of DNA-encoded libraries, highlighting key applications and future directions for this technology. Abstract | Full Text | PDF
Advertisement
Poster on Molecular mechanisms of amyotrophic lateral sclerosis This poster from Nature Reviews Neuroscience provides an overview of the molecular and cellular mechanisms that have been proposed to contribute to the pathogenesis of amyotrophic lateral sclerosis, which is the most common form of motor neuron disease.  Download free online   Funded by a grant from MT Pharma America, Inc
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.